A detailed history of Group One Trading, L.P. transactions in Voyager Therapeutics, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 246 shares of VYGR stock, worth $1,355. This represents 0.0% of its overall portfolio holdings.

Number of Shares
246
Holding current value
$1,355
% of portfolio
0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.77 - $9.27 $1,419 - $2,280
246 New
246 $1,000
Q4 2023

Feb 14, 2024

BUY
$6.28 - $8.81 $847 - $1,189
135 New
135 $1,000
Q1 2022

May 12, 2022

SELL
$2.75 - $9.44 $13,024 - $44,707
-4,736 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$2.47 - $5.55 $11,697 - $26,284
4,736 New
4,736 $13,000
Q2 2020

Aug 13, 2020

SELL
$8.05 - $14.21 $32,900 - $58,076
-4,087 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$6.8 - $14.66 $34,000 - $73,300
-5,000 Reduced 55.02%
4,087 $37,000
Q4 2019

Feb 10, 2020

BUY
$12.82 - $16.85 $116,495 - $153,115
9,087 New
9,087 $127,000
Q2 2019

Aug 09, 2019

SELL
$19.18 - $27.88 $1,918 - $2,788
-100 Closed
0 $0
Q1 2019

May 13, 2019

BUY
$8.0 - $19.66 $800 - $1,966
100 New
100 $2,000
Q4 2018

Feb 06, 2019

SELL
$8.59 - $18.05 $6,923 - $14,548
-806 Closed
0 $0
Q3 2018

Nov 08, 2018

SELL
$17.11 - $21.74 $1,711 - $2,174
-100 Reduced 11.04%
806 $15,000
Q2 2018

Aug 14, 2018

SELL
$16.76 - $23.92 $125,565 - $179,208
-7,492 Reduced 89.21%
906 $18,000
Q1 2018

May 11, 2018

BUY
$16.16 - $31.31 $135,711 - $262,941
8,398 New
8,398 $158,000
Q4 2017

Feb 09, 2018

SELL
$12.26 - $25.88 $118,272 - $249,664
-9,647 Closed
0 $0
Q3 2017

Nov 15, 2017

BUY
$8.37 - $20.59 $69,822 - $171,761
8,342 Added 639.23%
9,647 $199,000
Q2 2017

Aug 14, 2017

BUY
N/A
1,305
1,305 $12,000

Others Institutions Holding VYGR

About Voyager Therapeutics, Inc.


  • Ticker VYGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,647,600
  • Market Cap $213M
  • Description
  • Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...
More about VYGR
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.